---
title: 'High interobserver variability of PTEN immunohistochemistry defining PTEN
  status in low- to intermediate-risk prostate cancer: results of the first German
  ring trial'
date: '2024-12-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39653828/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241210175343&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: The prognostication of individual disease trajectory and selection of
  optimal therapy in patients with localized, low-grade prostate cancer often presents
  significant difficulty. The phosphatase and tensin homolog on chromosome 10 (PTEN)
  has emerged as a potential novel biomarker in this clinical context, based on its
  demonstrated prognostic significance in multiple retrospective studies. Incorporation
  into standard clinical practice necessitates exceptional diagnostic accuracy, and
  ...
disable_comments: true
---
The prognostication of individual disease trajectory and selection of optimal therapy in patients with localized, low-grade prostate cancer often presents significant difficulty. The phosphatase and tensin homolog on chromosome 10 (PTEN) has emerged as a potential novel biomarker in this clinical context, based on its demonstrated prognostic significance in multiple retrospective studies. Incorporation into standard clinical practice necessitates exceptional diagnostic accuracy, and ...